Literature DB >> 6114754

Characterization of alpha 2-adrenergic receptors in human platelets by binding of a radioactive ligand [3H]yohimbine.

A Mukherjee.   

Abstract

[3H]Yohimbine, a potent alpha 2-adrenergic antagonist, was used to label the alpha-adrenergic receptors in membranes isolated from human platelets. Binding of [3H]yohimbine to platelet membranes appears to have all the characteristics of binding to alpha-adrenergic receptors. Binding reached a steady state in 2-3 min at 37 degrees C and was completely reversible upon the addition of excess phentolamine or yohimbine (both at 10(-5) M; t1/2 = 2.37 min). [3H]Yohimbine bound to a single class of noncooperative sites with a dissociation constant of 1.74 nM. At saturation, the total number of binding sites was calculated to be 191 fmol/mg protein. [3H]Yohimbine binding was stereo-specifically inhibited by epinephrine: the (-) isomer was 11-times more potent that the (+) isomer. Catecholamine agonists competed for the occupancy of the [3H]yohimbine-binding sites with an order of potency: clonidine greater than (-)-epinephrine greater than (-)-norepinephrine much greater than (-)-isoproterenol. The potent alpha-adrenergic antagonist, phentolamine, competed for the sites whereas the beta-antagonist, (+/-)-propranolol, was very weak inhibitor. 0.1 mM GTP reduced the binding affinity of the agonists, while producing no change in antagonist-binding affinity. Dopamine and serotonin competed only at very high concentrations. Similarly, muscarinic cholinergic ligands were also poor inhibitors of [3H]yohimbine binding. These results suggest that [3H]yohimbine binding to hunan platelet membranes is specific, rapid, saturable, reversible and, therefore, can be successfully used to label alpha 2-adrenergic receptors.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6114754     DOI: 10.1016/0304-4165(81)90182-3

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  5 in total

1.  Variations in circulating catecholamines fail to alter human platelet alpha-2-adrenergic receptor number or affinity for [3H]yohimbine or [3H]dihydroergocryptine.

Authors:  M A Pfeifer; K Ward; T Malpass; J Stratton; J Halter; M Evans; H Beiter; L A Harker; D Porte
Journal:  J Clin Invest       Date:  1984-09       Impact factor: 14.808

2.  Binding of yohimbine stereoisomers to alpha-adrenoceptors in rat liver and human platelets.

Authors:  N Ferry; M Goodhardt; J Hanoune; T Sevenet
Journal:  Br J Pharmacol       Date:  1983-02       Impact factor: 8.739

3.  Alpha 2-adrenoceptors in platelets of spontaneously hypertensive rats.

Authors:  M Minuth; K H Jakobs
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1983-03       Impact factor: 3.000

4.  Acute reduction in human platelet alpha 2-adrenoreceptor affinity for agonist by endogenous and exogenous catecholamines.

Authors:  A S Hollister; G A FitzGerald; J H Nadeau; D Robertson
Journal:  J Clin Invest       Date:  1983-10       Impact factor: 14.808

5.  3H-Rauwolscine binding in platelets from depressed patients and healthy volunteers.

Authors:  C Pimoule; M S Briley; C Gay; H Loo; D Sechter; E Zarifian; R Raisman; S Z Langer
Journal:  Psychopharmacology (Berl)       Date:  1983       Impact factor: 4.530

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.